Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by. - 2Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- 36 Fledgling Cameras for 2024: Ideal for New Photographic artists
- 46 Web-based Course Stages for Successful Learning and Educating
- 5Discovery of massive spider's web in Greece reveals unexpected behavior
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- What really happens when 140 reality stars come face to face with their biggest fans
- 2024's Driving Clearing Robots: Master Suggestions and Surveys
- Putin critic gets six years in penal colony, vows hunger strike
- Katz alleges Army Radio workers misled High Court in bid to halt closure
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- Farmers call for French blockades over cow disease cull
